Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Clinical Management of Urticaria, Dermographism, PMLE, and Angioedema

Description

The presentation reviews practical management of urticaria and angioedema through several cases. A 25-year-old man with seven weeks of daily hives fits chronic spontaneous urticaria (CSU); the key points are to avoid repeated prednisone, up-dose antihistamines up to four times daily or switch to a stronger agent such as cetirizine, and reassure him that routine allergy testing and food or gluten causes are not indicated. A 34-year-old woman with itch and wheals induced by scratching and heat has dermatographism, a chronic inducible urticaria best managed with daily antihistamines, with advanced off-label options such as omalizumab, remibrutinib, or dupilumab if needed. A man who developed itchy plaques after vacation is diagnosed with polymorphous light eruption (PMLE), which can resemble hives and may be treated with scheduled antihistamines or a short prednisone course because it is usually transient. The speaker emphasizes that many patients are anxious and want a cause, so clinicians should explain the diagnosis, discuss prognosis, offer limited blood work if appropriate, and build trust rather than pursue routine allergy panels. Another woman with acute urticaria after an apparent viral illness is managed with expectation-setting, trigger avoidance, optional limited labs, and possibly short-term cyclosporine if symptoms are severe. For refractory CSU, a woman with severe hives and poor response to high-dose antihistamines and omalizumab may benefit from switching advanced therapy, such as trialing dupilumab. Finally, recurrent angioedema without hives should prompt evaluation for bradykinin-mediated causes such as ACE-inhibitor angioedema, hereditary angioedema, or acquired C1 inhibitor deficiency, whereas angioedema with hives is more likely part of CSU.

View more

Conclusions

Chronic spontaneous urticaria is diagnosed clinically after six or more weeks of near-daily hives, and routine allergy or food testing is usually unnecessary.
Prednisone may provide temporary relief but should generally be avoided as a repeated treatment strategy for CSU because it encourages dependence and does not address the underlying disease.
First-line management of CSU and dermatographism is regular, often up-dosed second-generation antihistamines, sometimes increased up to four times daily.
Patients with chronic inducible urticarias such as dermatographism also benefit from daily preventive antihistamine use rather than taking medication only when symptoms appear.
When standard antihistamines are inadequate, advanced therapies such as omalizumab, dupilumab, or remibrutinib may be used, including off-label for some chronic inducible urticarias.
Polymorphic light eruption can mimic urticaria clinically, but it is a distinct, usually transient photosensitive eruption that may respond to scheduled antihistamines or a short steroid course.
Successful urticaria care often depends as much on reassurance, expectation-setting, and empathy as on medication choice, especially for anxious patients seeking a root cause.
A limited, targeted laboratory evaluation can be reasonable when patients are worried about internal disease, but extensive testing for cancer or autoimmune disease is usually not indicated.
If omalizumab is only partially effective, switching to another advanced therapy such as dupilumab is a reasonable next step rather than persisting indefinitely with the same regimen.
Angioedema can accompany chronic urticaria and is often less severe and more rapidly resolving than bradykinin-mediated angioedema.
Angioedema without wheals should prompt evaluation for non-histaminergic causes such as ACE-inhibitor angioedema, hereditary angioedema, or acquired C1-inhibitor deficiency.
Overall, the presentation emphasizes a practical stepwise approach to urticaria that prioritizes accurate phenotyping, antihistamine optimization, selective use of advanced agents, and strong patient communication.